Cancer Vaccines: Looking to the Future

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2013 Jun 27

PMID 23802081

Citations 25

Authors

Kavitha Yaddanapudi

Robert A Mitchell

John W Eaton

Affiliations

Soon will be listed here.

Abstract

These are exciting times for the field of cancer immunotherapy. Although the clinical efficacy of monoclonal antibodies has been demonstrated since the early 1990s, the therapeutic profile of other immunotherapeutic approaches-especially vaccines-has not yet been formally clarified. However, the recent success of several immunotherapeutic regimens in cancer patients has boosted the development of this treatment modality. These achievements stemmed from recent scientific advances demonstrating the tolerogenic nature of cancer and the fundamental role of the tumor immune microenvironment in the suppression of antitumor immunity. New immunotherapeutic strategies against cancer attempt to promote protective antitumor immunity while disrupting the immunoregulatory circuits that contribute to tumor tolerance. Cancer vaccines differ from other anticancer immunotherapeutics in that they initiate the dynamic process of activating the immune system so as to successfully re-establish a state of equilibrium between tumor cells and the host. This article reviews recent clinical trials involving several different cancer vaccines and describes some of the most promising immunotherapeutic approaches that harness antitumor T-cell responses. In addition, we describe strategies whereby cancer vaccines can be exploited in combination with other therapeutic approach to overcome-in a synergistic fashion-tumor immunoevasion. Finally, we discuss prospects for the future development of broad spectrum prophylactic anticancer vaccines.

Citing Articles

The efficacy of an embryonic stem cell-based vaccine for lung cancer prevention depends on the undifferentiated state of the stem cells.

Meng S, Whitt A, Eaton J, Yaddanapudi K, Li C Sci Rep. 2024; 14(1):32127.

PMID: 39739089 PMC: 11685895. DOI: 10.1038/s41598-024-83932-0.

Biomimetic nanoparticles with red blood cell membranes for enhanced photothermal and immunotherapy for tumors.

Hong L, Ye J, Li Y, Yin S RSC Adv. 2024; 14(45):32818-32826.

PMID: 39429938 PMC: 11484151. DOI: 10.1039/d4ra06965j.

DNA Vaccines: Their Formulations, Engineering and Delivery.

Kozak M, Hu J Vaccines (Basel). 2024; 12(1).

PMID: 38250884 PMC: 10820593. DOI: 10.3390/vaccines12010071.

rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses.

Ye J, Wang H, Medina R, Chakraborty S, Sun M, Valenzuela A J Exp Clin Cancer Res. 2023; 42(1):163.

PMID: 37434263 PMC: 10337177. DOI: 10.1186/s13046-023-02744-8.

Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects.

Gupta M, Wahi A, Sharma P, Nagpal R, Raina N, Kaurav M Vaccines (Basel). 2022; 10(12).

PMID: 36560420 PMC: 9788126. DOI: 10.3390/vaccines10122011.

References

Lyerly H . Quantitating cellular immune responses to cancer vaccines. Semin Oncol. 2003; 30(3 Suppl 8):9-16. DOI: 10.1016/s0093-7754(03)00230-6. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Jinushi M, Hodi F, Dranoff G . Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev. 2008; 222:287-98. DOI: 10.1111/j.1600-065X.2008.00618.x. View

Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G . Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer. 1995; 63(6):883-5. DOI: 10.1002/ijc.2910630622. View

Cutts F, Hall A . Vaccines for neonatal viral infections: hepatitis B vaccine. Expert Rev Vaccines. 2004; 3(4):349-52. DOI: 10.1586/14760584.3.4.349. View

Coussens L, Yang-Feng T, Liao Y, Chen E, Gray A, McGrath J . Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985; 230(4730):1132-9. DOI: 10.1126/science.2999974. View

Brichard V, Lejeune D . GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine. 2007; 25 Suppl 2:B61-71. DOI: 10.1016/j.vaccine.2007.06.038. View

Litzinger M, Fernando R, Curiel T, Grosenbach D, Schlom J, Palena C . IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007; 110(9):3192-201. PMC: 2200901. DOI: 10.1182/blood-2007-06-094615. View

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K . Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993; 90(8):3539-43. PMC: 46336. DOI: 10.1073/pnas.90.8.3539. View

10.

Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

11.

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C . Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012; 18(8):1254-61. DOI: 10.1038/nm.2883. View

12.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

13.

Dovey J, Zacharek S, Kim C, Lees J . Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc Natl Acad Sci U S A. 2008; 105(33):11857-62. PMC: 2575250. DOI: 10.1073/pnas.0803574105. View

14.

Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D . Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2:14631-8. PMC: 521999. DOI: 10.1073/pnas.0405743101. View

15.

Jaffee E, Hruban R, Biedrzycki B, Laheru D, Schepers K, Sauter P . Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001; 19(1):145-56. DOI: 10.1200/JCO.2001.19.1.145. View

16.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

17.

van Elsas A, Hurwitz A, Allison J . Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors.... J Exp Med. 1999; 190(3):355-66. PMC: 2195583. DOI: 10.1084/jem.190.3.355. View

18.

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

19.

Rasku M, Clem A, Telang S, Taft B, Gettings K, Gragg H . Transient T cell depletion causes regression of melanoma metastases. J Transl Med. 2008; 6:12. PMC: 2330026. DOI: 10.1186/1479-5876-6-12. View

20.

Singh-Jasuja H, Emmerich N, Rammensee H . The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother. 2004; 53(3):187-95. PMC: 11032959. DOI: 10.1007/s00262-003-0480-x. View